Successful management of an arteriovenous malformation with trametinib in a patient with capillary-malformation arteriovenous malformation syndrome and cardiac compromise

Cynthia L. Nicholson; Siobhan Flanagan; Michael Murati; Christina Boull; Erin McGough; Rebecca Ameduri; Brenda Weigel; Sheilagh Maguiness

doi:10.1111/pde.14912

Successful management of an arteriovenous malformation with trametinib in a patient with capillary-malformation arteriovenous malformation syndrome and cardiac compromise

Cynthia L. Nicholson, Siobhan Flanagan, Michael Murati, Christina Boull, Erin McGough, Rebecca Ameduri, Brenda Weigel, Sheilagh Maguiness

Research output: Contribution to journal › Article › peer-review

17 Scopus citations

Abstract

Capillary malformation-arteriovenous malformation (CM-AVM) syndrome is an autosomal dominant condition characterized by multifocal, noncontiguous pink patches on the skin that often have a surrounding pale halo. In some cases, an association with a fast flow, arteriovenous malformation (AVM) can be identified. Here, we describe a case report of a 16-year-old woman with CM-AVM syndrome and significant cardiac compromise successfully treated with trametinib, a mitogen-activated protein kinase (MEK) inhibitor.

Original language	English (US)
Pages (from-to)	316-319
Number of pages	4
Journal	Pediatric Dermatology
Volume	39
Issue number	2
DOIs	https://doi.org/10.1111/pde.14912
State	Published - Mar 1 2022

Bibliographical note

Funding Information:
The authors thank Timothy Moss, MD PhD and Denise Adams, MD for their aid in the management decisions in this case.

Publisher Copyright:
© 2022 Wiley Periodicals LLC.

Keywords

MEK inhibitor
skin signs of systemic disease
therapy-systemic
trametinib
vascular malformation

PubMed: MeSH publication types

Case Reports
Journal Article

Access

10.1111/pde.14912

OpenUrl availability

Full text

Cite this

Successful management of an arteriovenous malformation with trametinib in a patient with capillary-malformation arteriovenous malformation syndrome and cardiac compromise. / Nicholson, Cynthia L.; Flanagan, Siobhan ; Murati, Michael et al.
In: Pediatric Dermatology, Vol. 39, No. 2, 01.03.2022, p. 316-319.

Research output: Contribution to journal › Article › peer-review

@article{24eafc12fec348d3b799138e6b189f48,

title = "Successful management of an arteriovenous malformation with trametinib in a patient with capillary-malformation arteriovenous malformation syndrome and cardiac compromise",

abstract = "Capillary malformation-arteriovenous malformation (CM-AVM) syndrome is an autosomal dominant condition characterized by multifocal, noncontiguous pink patches on the skin that often have a surrounding pale halo. In some cases, an association with a fast flow, arteriovenous malformation (AVM) can be identified. Here, we describe a case report of a 16-year-old woman with CM-AVM syndrome and significant cardiac compromise successfully treated with trametinib, a mitogen-activated protein kinase (MEK) inhibitor.",

keywords = "MEK inhibitor, skin signs of systemic disease, therapy-systemic, trametinib, vascular malformation",

author = "Nicholson, {Cynthia L.} and Siobhan Flanagan and Michael Murati and Christina Boull and Erin McGough and Rebecca Ameduri and Brenda Weigel and Sheilagh Maguiness",

note = "Funding Information: The authors thank Timothy Moss, MD PhD and Denise Adams, MD for their aid in the management decisions in this case. Publisher Copyright: {\textcopyright} 2022 Wiley Periodicals LLC.",

year = "2022",

month = mar,

day = "1",

doi = "10.1111/pde.14912",

language = "English (US)",

volume = "39",

pages = "316--319",

journal = "Pediatric Dermatology",

issn = "0736-8046",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - Successful management of an arteriovenous malformation with trametinib in a patient with capillary-malformation arteriovenous malformation syndrome and cardiac compromise

AU - Nicholson, Cynthia L.

AU - Flanagan, Siobhan

AU - Murati, Michael

AU - Boull, Christina

AU - McGough, Erin

AU - Ameduri, Rebecca

AU - Weigel, Brenda

AU - Maguiness, Sheilagh

PY - 2022/3/1

Y1 - 2022/3/1

N2 - Capillary malformation-arteriovenous malformation (CM-AVM) syndrome is an autosomal dominant condition characterized by multifocal, noncontiguous pink patches on the skin that often have a surrounding pale halo. In some cases, an association with a fast flow, arteriovenous malformation (AVM) can be identified. Here, we describe a case report of a 16-year-old woman with CM-AVM syndrome and significant cardiac compromise successfully treated with trametinib, a mitogen-activated protein kinase (MEK) inhibitor.

AB - Capillary malformation-arteriovenous malformation (CM-AVM) syndrome is an autosomal dominant condition characterized by multifocal, noncontiguous pink patches on the skin that often have a surrounding pale halo. In some cases, an association with a fast flow, arteriovenous malformation (AVM) can be identified. Here, we describe a case report of a 16-year-old woman with CM-AVM syndrome and significant cardiac compromise successfully treated with trametinib, a mitogen-activated protein kinase (MEK) inhibitor.

KW - MEK inhibitor

KW - skin signs of systemic disease

KW - therapy-systemic

KW - trametinib

KW - vascular malformation

UR - http://www.scopus.com/inward/record.url?scp=85122675099&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85122675099&partnerID=8YFLogxK

U2 - 10.1111/pde.14912

DO - 10.1111/pde.14912

M3 - Article

C2 - 35014097

AN - SCOPUS:85122675099

SN - 0736-8046

VL - 39

SP - 316

EP - 319

JO - Pediatric Dermatology

JF - Pediatric Dermatology

IS - 2

ER -

Successful management of an arteriovenous malformation with trametinib in a patient with capillary-malformation arteriovenous malformation syndrome and cardiac compromise

Abstract

Bibliographical note

Keywords

PubMed: MeSH publication types

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this